Effects of rankl inhibitor on hormonal parameters in letrozole induced rat model of polycystic ovary syndrome.

Abstract

Objective: To study the effect of RANKL inhibitor on serum FSH, LH and testosterone level in Letrozole induced rat model of PCOS. Study Design: Experimental Animal study. Setting: Thirty adult female Wistar Albino rats of 6-8 weeks of age with a weight range of 120–150 gm were recruited from the animal house of Baqai Medical University. Period: February 2022 till August 2022. Material & Methods: The rats were randomly divided into A, B, and C groups and each contained 10 rats. Group A was considered ass control while Group B served as Letrozole induced PCOS group and Group C served as RANKL inhibitor group. Letrozole dissolved in 0.1% CMC and was given at a dose of 1 mg/kg orally for 21 days to induce PCOS. RANKL inhibitor (Denosumab) was given 0.25 mg/kg body weight subcutaneously for 4 weeks after the induction of PCOS i.e from 21 days to 50th days. At the end of the experiment, blood was taken from intra cardiac puncture and analyzed through ELISA. Results: Mean serum level of LH and testosterone level were significantly higher (P<0.001) in Letrozole-treated PCOs group which was significantly decreased (P<0.001) in Denosumab treated animals but significantly higher (P<0.05) than control group. Whereas, mean serum FSH level was significantly (P<0.01) lower in the Letrozole-treated group which was significantly increased in Denosumab treated animals but significantly lower (P<0.05) than the control group. Conclusion: RANKL inhibitor could prevent the hormonal imbalance in letrozole treated PCOs in albino rats.